Effects of remifentanil on pharyngeal swallowing and esophageal motility: no impact of different bolus volumes, and partial antagonism by methylnaltrexoneShow others and affiliations
2021 (English)In: American Journal of Physiology - Gastrointestinal and Liver Physiology, ISSN 0193-1857, E-ISSN 1522-1547, Vol. 321, no 4, p. G367-G377Article in journal (Refereed) Published
Abstract [en]
Background: Remifentanil impairs swallowing, and disturbed accommodation to bolus volume may be one of the underlying causes. It is not fully understood whether remifentanil-induced swallowing dysfunction is mediated by peripheral or central mechanisms.
Aims: To investigate if remifentanil-induced swallowing dysfunction is dependent on the bolus volume and whether the effect of remifentanil could be counteracted by methylnaltrexone, a peripherally acting opioid antagonist.
Methods: Nineteen healthy volunteers were included in this double-blinded, randomized, placebo-controlled, crossover study. Study participants received target-controlled remifentanil infusions and placebo infusions in a randomized order. Methylnaltrexone was administered by intravenous injection of doses of 0.3 mg/kg. Recordings of pressure and impedance data were acquired using a combined manometry and impedance solid state catheter. Data was analyzed from three series of bolus swallows, baseline, during remifentanil exposure, and 15 min after methylnaltrexone.
Results: Remifentanil induced significant effects on multiple pharyngeal and esophageal function parameters. No significant differences in remifentanil-induced swallowing dysfunction related to different bolus volumes were found. Pharyngeal effects of remifentanil were not significantly counteracted by methylnaltrexone, whereas on the distal esophageal level, effects on distension pressures were counteracted. Conclusions Changes in pharyngeal and esophageal pressure flow variables were consistent with previous results on remifentanil-induced swallowing dysfunction, and uniform across all bolus volumes. The effects of remifentanil on the pharyngeal level and on the proximal esophagus appear to be predominantly centrally mediated, whereas the effects of remifentanil on the distal esophagus may be mediated by both central and peripheral mechanisms.
NEW & NOTEWORTHY: In this randomized controlled trial, we used the "Swallow Gateway" online platform to analyze the effects of remifentanil on pharyngeal and esophageal swallowing. It is not fully understood whether remifentanil-induced swallowing dysfunction is mediated by peripheral or central mechanisms. By using methylnaltrexone, we demonstrated that effects of remifentanil on pharyngeal swallowing were predominantly centrally mediated, whereas its effects on the distal esophagus may be mediated by both central and peripheral mechanisms.
Place, publisher, year, edition, pages
HighWire Press , 2021. Vol. 321, no 4, p. G367-G377
Keywords [en]
Esophageal Motility, Methylnaltrexone, Pharyngeal swallowing, Remifentanil
National Category
Anesthesiology and Intensive Care
Identifiers
URN: urn:nbn:se:oru:diva-93483DOI: 10.1152/ajpgi.00137.2021ISI: 000701776200002PubMedID: 34261364Scopus ID: 2-s2.0-85117033838OAI: oai:DiVA.org:oru-93483DiVA, id: diva2:1584454
Note
Funding agencies:
Research Fund of the Örebro County Council
ALF research funding (Örebro University)
University of Turku
National Health and Medical Research Council of Australia
2021-08-122021-08-122023-04-28Bibliographically approved
In thesis